16 October 2015 - PHARMAC is seeking feedback on proposals to list two new treatments for Multiple Sclerosis (MS) – dimethyl fumarate and teriflunomide and to make amendments to the Special Authority criteria relating to MRI requirements for all MS treatments.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-10-16-ms-treatments/